Skip to main content
News Icon

News categories: Publication

Malaria Causes Permanent Damage to Phagocytes in the Spleen

Macrophages formed in the bone marrow can only assume the function of embryonal phagocytes, or “scavenger cells,” to a certain degree according to a study by the University of Bonn and the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. The researchers have demonstrated that malaria infection causes permanent damage to resident CD163 macrophages in the spleen, which are responsible for cleaning the blood, recycling iron and communicating with other cells involved in the body’s immune response. Their findings could harbor potential not only for more effective malaria vaccines but also for developing drugs and treatments to combat other infectious diseases. The paper is to be published in the journal “Immunity” but can already be accessed online.

Macrophages are an important component in our immune system. As part of our nonspecific defenses, these “big eaters” serve as our body’s “cleanup crew,” tracking down pathogens, removing dead cells and digesting foreign substances to make them harmless. “Macrophages essentially come in two different kinds: resident ones, which develop in the embryo, and recruited ones, which can be newly formed at any time,” explains Professor Elvira Mass, head of the Developmental Biology of the Immune System working group at the University of Bonn’s Life & Medical Sciences Institute (LIMES).

Resident macrophages regenerate through cell division. If many of them are destroyed as a result of a severe infection or injury, they cannot divide quickly enough to keep up. In that case, their role is assumed by white blood cells, which are created in the bone marrow and which then develop into macrophages. “People used to assume that this replacement was virtually 1:1, but our latest research shows this not to be the case,” Mass explains.

 

Malaria infection causes lasting damage to macrophage population

In a joint study together with Dr. Lynette Beattie’s working group at the Peter Doherty Institute for Infection and Immunity in Melbourne, Mass’s group investigated the long-term impact of malaria infection on resident macrophages in the spleen. “The spleen is home to a large population of macrophages that eat dead red blood cells, recycling iron in the process. They possess a receptor called CD163, hence the name ‘CD163 macrophages,’” says Mass, who is also Speaker for the University of Bonn’s Life and Health Transdisciplinary Research Area and a member of its ImmunoSensation3 Cluster of Excellence.

By running experiments on genetically altered mice, the researchers were able to show that the presence of the malaria parasites, which live in and cause lysis of red blood cells, results in a long-lasting loss of the CD163 macrophages during the “blood stage” of the infection i.e. the phase in which the characteristic bouts of fever occur. Even months after the infection had subsided, the CD163 population had not recovered. “Their places are taken by new cells originating in the bone marrow, although these cells don’t attain the same degree of specialization as the originals,” Mass explains. This is a problem because CD163 macrophages also control parts of the immune response in addition to their scavenging role. Specifically, they use a signaling molecule to communicate with macrophages in the marginal zone (an important structural component of the spleen). “This structure helps to make sure that the immune cells in the spleen can get the signals that they need to fight bacteria and viruses, and we found that this structure and the associated communication network is persistently damaged by malaria” said Dr Beattie, the co-lead of the study. 

A series of follow-up experiments confirmed that eliminating the signaling molecule is enough to shrink the macrophage population in the marginal zone. If the CD163 macrophages are depleted, a malaria infection will be more severe, releasing more malaria-causing parasites into the bloodstream and making anemia last longer. And, because this damage is not just temporary, the prognosis for repeat infections is also significantly worse.

 

Findings can be applied to human beings

Given that CD163 macrophages are also present in our own spleen, the researchers believe that malaria causes a permanent change in the human macrophage architecture too. “Our results indicate that a single malaria episode can leave a lasting impression on the immunological memory, particle filtering and the spleen’s iron metabolism,” Mass reveals. “This could be relevant for vaccine effectiveness, especially in parts of the world where malaria infections occur repeatedly.”

The study also does much to improve our understanding of how resident and recruited macrophages are formed, work and interact. In an ideal scenario, this could accelerate the development of drugs and treatments not only for malaria but also for other diseases.

 

Institutions involved and funding secured

Alongside the University of Bonn and the Doherty Institute in Melbourne, the study also involved the University of New South Wales (Sydney, Australia), the Gulbenkian Institute for Molecular Medicine (Lisbon, Portugal), the Gustave Roussy Cancer Campus (Villejuif, France), the Shanghai Institute of Immunology (Shanghai, China), the Singapore Immunology Network and the Translational Immunology Institute (both Singapore). The project was funded by the Boehringer Ingelheim Foundation, the ImmunoSensation3 Cluster of Excellence at the University of Bonn, the IRTG 2168 Research Training Group and a Global Fund at the TRA Life and Health.

 

Publication

Katharina Mauel, Daria Hirschmann, Nelli Blank-Stein, Marie-Louise Diefenbach-Wilke, Theresa Eulgem, Shirley Le, Samuel N. Breit, Miguel P. Soares, Vicky Wang-Wei Tsai, Florent Ginhoux, William R. Heath, Lynette Beattie and Elvira Mass: “CD163+ red pulp macrophages interact with marginal metallophilic macrophages during blood-stage malaria to maintain splenic architecture,” in: “Immunity 2026,” https://doi.org/10.1016/j.immuni.2026.07.006

 

Media contact:

Prof. Dr. Elvira Mass
Life & Medical Sciences Institute (LIMES)
University of Bonn
Phone: +49 228 73-62786
Email: elvira.mass@uni-bonn.de 

 

Aline Riche 
Communications and Media Manager
Doherty Institute, Australia
Phone: +61 (0) 3 8344 1911 
Mobile: +61 (0) 403 204 336 
Email: Doherty-media@unimelb.edu.au 

Related news

Tracking glioblastoma cell spread in human brain tissue

News categories: Publication

Core2Edge: How tumor cells conquer the brain

Glioblastoma is an aggressive brain tumor that infiltrates deep into the surrounding brain tissue. Even after surgery, tumor cells remain in the brain and the tumor recurs. Bonn researchers have now developed Core2Edge, a model based entirely on human tissue that captures these hard-to-access infiltration zones at the tumor margin. The model enables investigation of the invasive front and direct assessment of new drug candidates in human tissue - without the need for animal testing. The study of the Brain Tumor Translational Research Group has now been published in Nature Protocols.
View entry
Mikrochip zur Wiederherstellung zentralen Sehvermögens bei fortgeschrittener Makuladegeneration.

News categories: Publication

Approval of a Novel Retinal Implant Technology

A novel retinal implant is offering people with geographic atrophy the opportunity to regain part of their central vision for the first time. Geographic atrophy is a severe late stage of age-related macular degeneration. An international research team led by Prof. Frank G. Holz of the UKB and the University of Bonn demonstrated in an international clinical trial that the majority of participants experienced significant improvements in visual acuity. The novel retinal implant technology has now received approval for routine clinical use in Europe, making it available beyond clinical trials.
View entry
Authors

News categories: Publication

The Gut as a Key Player in Immunotherapy for MS

B-cell depletion therapies, in which B cells of the immune system, which may drive disease activity in multiple sclerosis (MS), are temporarily removed, have contributed significantly to improved treatment for patients in recent years. Researchers from Bonn, along with their collaborators, have uncovered a previously unknown mechanism through which B-cell depletion therapies contribute to a better disease course in patients with MS. Surprisingly, the treatment appears to exert part of its beneficial effect by mobilizing regulatory immune cells that naturally reside in the gut.
View entry

Back to the news overview